Carisma Therapeutics: Funding, Investors & Team (Aug 2026)
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease. Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania.
Carisma Therapeutics has raised $89.0M across 3 funding rounds on record, the most recent a Series C of $30.0M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Carisma Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Carisma Therapeutics Funding Rounds
Carisma Therapeutics raised $47.0M in a Series B announced in Jan 2021.
2 months later, a Series B of $12.0M was announced in Mar 2021.
1.5 years later, a Series C of $30.0M was announced in Sep 2022.
Carisma Therapeutics Founders and Leadership Team
Contact details for the Carisma Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Carisma Therapeutics Funding Compared to Other Biotechnology Startups
Carisma Therapeutics' latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Carisma Therapeutics in Biotechnology and Philadelphia
Companies Similar to Carisma Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Carisma Therapeutics Funding FAQs
What does Carisma Therapeutics do?
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease. Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania.
How much funding has Carisma Therapeutics raised?
Carisma Therapeutics has raised $89.0M across 3 rounds on record. The most recent is a Series C of $30.0M announced in Sep 2022.
When did Carisma Therapeutics last raise funding?
Carisma Therapeutics' most recent funding round on record is a Series C of $30.0M, announced in Sep 2022.
Who founded Carisma Therapeutics?
FundedIQ lists Saar Gill (Founder) at Carisma Therapeutics.
Who is the CEO of Carisma Therapeutics?
Steven Kelly is listed as CEO at Carisma Therapeutics.
Where is Carisma Therapeutics headquartered?
Carisma Therapeutics is based in Philadelphia, Pennsylvania, United States.
How many employees does Carisma Therapeutics have?
Carisma Therapeutics is in the 51-100 employee band.
How does Carisma Therapeutics' funding compare to other Biotechnology startups?
Carisma Therapeutics' latest round of $30.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Carisma Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Carisma Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.